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Abstract
To evaluate outcome of breast cancer IM and SC node involvement, we evaluated 107 patients with IM or SC
node involvement and a matched cohort of patients as controls. Patients with SC node involvement had a
signiﬁcantly poorer DFS and higher loco-regional recurrence rates compared with controls without SC node
involvement.
Background: The prognostic implications of internal mammary (IM) and supraclavicular (SC) node involvement in
locally advanced breast cancer is still unclear. Patients and Methods: We evaluated 107 patients with IM (n ¼ 65) or
SC (n ¼ 42) node involvement who underwent operation at the European Institute of Oncology between 1997 and
2009 to assess their prognostic features. We subsequently analyzed matched cohorts, using the 107 patients as cases
and another group of patients as a control cohort, to evaluate prognostic differences between patients with and those
without IM or SC node involvement. Results: Five-year disease-free survival (DFS) was 84% in IM vs. 38.8% in SC
node involvement (P < .0001), and 5-year overall survival (OS) was 96.9% in IM node vs. 57.1% in SC node
involvement (P < .0001). No difference in outcome was found between patients with and controls without IM node
involvement. Conversely, a statistically signiﬁcant difference in DFS and locoregional recurrence was observed in
patients with SC node involvement compared with controls without SC node involvement. Conclusion: SC node
involvement correlated with a signiﬁcantly poorer outcome in patients with locally advanced breast cancer. Adequate
staging, including biopsy of suspicious locoregional ipsilateral lymph nodes, is mandatory in these patients. Patients
with IM or SC node involvement should be treated with curative intent using combined-modality treatments.
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Introduction and costal cartilages. The nodes are generally located close to the IM
The precise prognostic signiﬁcance of internal mammary (IM)
chain and supraclavicular (SC) lymph node involvement in patients
with locally advanced breast cancer is still debated, and therapeutic
choices in patients in whom IM or SC lymph nodes (or both) are
involved are still not uniformly deﬁned.
The IM lymph node chain is represented by a variable number of
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Table 1 Baseline Characteristics of Patients With SC or IM Node Metastases and Matched Groups
Variable
Patients by Type of Node Metastasis Group
Internal Mammary
(n [ 65)
Control Group
(n [ 65) P Valuea
Ipsilateral
Supraclavicular
(n [ 42)
Control Group
(n [ 42) P Valueb P Valuec
n (%) n (%) n (%) n (%)
Matching Variables
Neoadjuvant therapy e e <.0001
No 56 (86.2) 56 (86.2) 13 (31) 13 (31)
Yes 9 (13.8) 9 (13.8) 29 (69) 29 (69)
Year of surgery e e <.0001
Before 2000 0 (0) 3 (4.6) 11 (26.2) 6 (14.3)
2000-2003 27 (41.5) 28 (43.1) 24 (57.1) 25 (59.5)
2003-2006 23 (35.4) 13 (20) 3 (7.1) 6 (14.3)
2007-2009 15 (23.1) 21 (32.3) 4 (9.5) 5 (11.9)
Age (years) e e .007
<35 4 (6.2) 3 (4.6) 2 (4.8) 2 (4.8)
35-50 35 (53.8) 35 (53.8) 9 (21.4) 11 (26.2)
51-65 21 (32.3) 21 (32.3) 25 (59.5) 26 (61.9)
>65 5 (7.7) 6 (9.2) 6 (14.3) 3 (7.1)
Positive lymph nodes at
surgery (n)
e e <.0001
None 1 (1.5) 1 (1.5) 7 (16.7) 7 (16.7)
1-3 33 (50.8) 33 (50.8) 4 (9.5) 4 (9.5)
4-9 14 (21.5) 14 (21.5) 6 (14.3) 6 (14.3)
10þ 17 (26.2) 17 (26.2) 25 (59.5) 25 (59.5)
pT status e e <.0001
pT0 1 (1.5) 1 (1.5) 6 (14.3) 6 (14.3)
pT1 25 (38.5) 25 (38.5) 10 (23.8) 10 (23.8)
pT2 30 (46.2) 30 (46.2) 9 (21.4) 9 (21.4)
pT3-4 9 (13.8) 9 (13.8) 17 (40.5) 17 (40.5)
Tumor subtype e e .002
Luminal A 11 (16.9) 13 (20) 2 (4.8) 8 (19)
Luminal B (Ki67 14) 38 (58.5) 38 (58.5) 11 (26.2) 10 (23.8)
Luminal B (HER2þ) 8 (12.3) 7 (10.8) 3 (7.1) 3 (7.1)
HER2þ 3 (4.6) 2 (3.1) 7 (16.7) 4 (9.5)
Triple negative 4 (6.2) 4 (6.2) 8 (19) 8 (19)
NA 1 (1.5) 1 (1.5) 11 (26.2) 9 (21.4)
Other Prognostic Factors
Histologic type .060 .128 .918
Negative 0 (0) 1 (1.5) 2 (4.8) 2 (4.8)
Ductal 54 (83.1) 44 (67.7) 32 (76.2) 27 (64.3)
Lobular 3 (4.6) 11 (16.9) 2 (4.8) 8 (19)
Other 8 (12.3) 9 (13.8) 6 (14.3) 5 (11.9)
Grade .501 .004 .001
Unknown 11 (16.9) 12 (18.5) 26 (61.9) 33 (78.6)
1-2 35 (53.8) 31 (47.7) 3 (7.1) 7 (16.7)
3 19 (29.2) 22 (33.8) 13 (31) 2 (4.8)
PVI .129 .387 .850
Absent 28 (43.1) 35 (53.8) 18 (42.9) 21 (50)
Present 10 (15.4) 13 (20) 5 (11.9) 3 (7.1)
Focal 3 (4.6) 5 (7.7) 1 (2.4) 4 (9.5)
Diffuse 24 (36.9) 12 (18.5) 18 (42.9) 14 (33.3)
IM or SC Nodes Breast Cancer Metastases
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Table 1 Continued
Variable
Patients by Type of Node Metastasis Group
Internal Mammary
(n [ 65)
Control Group
(n [ 65) P Valuea
Ipsilateral
Supraclavicular
(n [ 42)
Control Group
(n [ 42) P Valueb P Valuec
n (%) n (%) n (%) n (%)
Treatment
Surgery .584 .369 .001
Conservative 43 (66.2) 40 (61.5) 14 (33.3) 18 (42.9)
Mastectomy 22 (33.8) 25 (38.5) 28 (66.7) 24 (57.1)
Radiotherapy .0004 .332 .056
No 1 (1.5) 14 (21.5) 4 (9.5) 7 (16.7)
Yes 64 (98.5)d 51 (78.5) 38 (90.5)d 35 (83.3)
CT/HT .144 .375 <.0001
No 1 (1.5) 1 (1.5) 5 (11.9) 4 (9.5)
HT 9 (13.8) 20 (30.8) 15 (35.7) 12 (28.6)
CT 7 (10.8) 6 (9.2) 15 (35.7) 12 (28.6)
HT-CT 48 (73.8) 38 (58.5) 7 (16.7) 14 (33.3)
Abbreviations: CT ¼ computed tomography; HT ¼ hormonal therapy; IM ¼ internal mammary; NA ¼ not available; PVI ¼ peritumoral vascular invasion; RT ¼ radiotherapy; SC ¼ supraclavicular.
ac2 test comparing proportions between IM group and control group.
bc2 test comparing proportions between ipsilateral SC group and control group.
cc2 test comparing proportions between IM group and ipsilateral SC group.
dIn the MI group, 1 patient received external RT, 2 patients received external RT plus IM chain RT, 34 patients locoregional RT, 9 patients locoregional RT plus IM chain RT, 3 patients IM chain RT, 3
patients received electron beam intraoperative radiotherapy (ELIOT), 12 patients received ELIOT plus external RT. In the SC group, 3 patients received external RT, 33 received locoregional RT, 1
received SC RT, 1 received ELIOT plus external RT.
Silvia Dellapasqua et alIM node involvement.2 In 1971, Urban and Marjani developed a
radical surgical approach and claimed that prognosis of patients with
breast cancer was improved by radical dissection of lymph nodes of
the ﬁrst to third spaces.3 An international randomized trial was
conducted by 5 cancer institutes in 1963 to 1966. A total of 1443
patients were randomized to either mastectomy or mastectomy plus
IM node dissection. Five-year (70%),4 10-year (60.7% vs. 57%,
respectively),5 and 30-year survival (approximately 20%)6 was
identical both in patients who received mastectomy alone and in
patients who underwent mastectomy and IM node dissection.
However, the review of 1119 cases treated with IM node dissection
showed that IM node involvement plays an important role as a
prognostic factor: 10-year survival varied from 80.4% in patients
with axillary and IM negative nodes to 30.0% in patients with both
nodal sites involved. Intermediate survival rates (54.6% and 53.0%)
were found when 1 or the other of the nodal stations (axillary and
IM) was affected separately.7 Moreover, many series of patients
treated with radiotherapy of the IM chain after mastectomy showed
a limited improvement in survival.8
Until recent years, the diagnosis of an SC ipsilateral adenopathy
in the staging of locally advanced breast cancer was included in the
stage IV category of tumor classiﬁcation, even without evidence of
further distant disease. Ipsilateral SC metastases from breast cancer
are considered an ominous sign, representing a late stage of regional
metastases, and despite aggressive local and regional treatment, cure
is rare. Most patients have distant metastases within 1 year of
detection of SC lymph node involvement. Radiotherapy alone or in
combination with surgical resection was the standard of care pre-
viously. Although high local control rates were observed with thistreatment strategy, survival for patients treated only with local
therapy was dismal. In a trial conducted at the MD Anderson
Cancer Center, 70 patients with ipsilateral SC adenopathy without
evidence of distant disease received treatment in 3 prospective trials
of neoadjuvant chemotherapy and then underwent mastectomy
and axillary lymph node dissection and subsequent adjuvant
chemotherapy followed by radiotherapy. Patients older than 50
years with estrogen receptorepositive tumors received tamoxifen
for 5 years. At a median follow-up of 11.6 years (range, 4.8-22.6
years), disease-free survival (DFS) rates at 5 and 10 years were 34%
and 32%, respectively. Overall survival (OS) rates at 5 and 10 years
were 41% and 31%, respectively. The authors concluded that
patients with ipsilateral SC metastases but no other evidence of
distant metastases warrant combined-modality treatments (chemo-
therapy, surgery, and radiotherapy) administered with curative
intent and proposed that patients with ipsilateral SC metastases
should be included in the stage IIIB category of the tumor-node-
metastasis classiﬁcation because their clinical course and prognosis
are similar to those of patients with stage IIIB locally advanced
breast cancer.9
We conducted a retrospective analysis of 107 patients with either
IM or SC lymph node involvement to evaluate prognostic features
of these 2 disease presentations. We subsequently conducted an
analysis based on matched cohorts, using the 107 patients described
previously as cases and a control cohort of patients with the same
clinicopathologic features, who had either undergone or had not
undergone previous neoadjuvant chemotherapy, to evaluate prog-
nostic differences between patients with and those without IM or
SC node involvement.Clinical Breast Cancer February 2014 - 55
Table 2 Observed First Events and Deaths in Patients with Breast Cancer Presenting With Ipsilateral SC or IM Lymph Node Metastases and
of 2 Matched Comparison Groups
Event
Patients by Type of Node Metastases Group
Internal Mammary
(n [ 65)
Comparison Group
(n [ 65)
Ipsilateral Supraclavicular
(n [ 42)
Comparison Group
(n [ 42)
n (%) n (%) n (%) n (%)
Observed First Event 21 (32.3) 18 (27.7) 27 (64.3) 21 (50.0)
Locoregional Event 4 5 10 4
Distant Metastases 7 9 15 13
Others 10 4 2 4
Observed deaths 7 (10.7) 7 (10.7) 19 (45.2) 12 (28.6)
IM or SC Nodes Breast Cancer Metastases
56 -Patients and Methods
Patients
We extracted information from our institutional database, which
includes data of all consecutive patients with breast cancer operated
on at the European Institute of Oncology. We identiﬁed 107 pa-
tients (the study group) with either IM or SC lymph node
involvement operated on between 1997 and 2009. Of these, 65
patients had IM lymph node involvement and 42 had SC lymph
node involvement (2 patients presented with both IM and SC
involvement and were included in the SC group).
In the IM group, diagnosis was determined from results obtained
by lymph node biopsy in 56 patients, positron emission tomogra-
phy in 8 patients, and lymph node ultrasonography in 1 patient.
In the SC group, diagnosis was determined by clinical visit in 23
patients and results from lymph node biopsy in 15 patients, posi-
tron emission tomography in 2 patients, and lymph node ultraso-
nography in 2 patients.
Patients might have received (n ¼ 38) or not received (n ¼ 69)
neoadjuvant treatment. Patients with metastatic disease at the time
of surgery, those with bilateral breast cancer, and those with a
history of previous cancer (other than skin cancer) were excluded.
Clinicopathologic data including age, tumor size, axillary lymph
node status, tumor subtype (luminal A, luminal B, triple negative,
and HER2-positive [HERþ]), tumor type (ductal, lobular, or other),
tumor grade, peritumoral vascular invasion, estrogen receptor (ER)
and progesterone receptor (PR) status, HER2 overexpression/ampli-
ﬁcation status, proliferative fraction (Ki-67), type of surgery, radio-
therapy, and type of systemic treatment (either neoadjuvant or
adjuvant) were recorded in a database and included in the analysis.
For each patient in the study group, we selected from the same
database 1 matched patient (control group). The variables used to
make the randomly assigned matches were as follows: age (within 5
years), tumor size at surgery (pT0, pT1, pT2, pT3-4), number of
positive lymph nodes at surgery (none, 1-3, 4-9, > 9), tumor
subtype (luminal A, luminal B, triple negative, HER2þ), and year of
surgery (within 2 years). For 18 cases, no controls satisfying all the
criteria could be found. For these cases, matching criteria were
relaxed (ie, age within 10 years or year of surgery within 3 years) or
not considered (ie, tumor subtype).
Pathologic and Immunohistochemical Analysis
All patients had pathologic evaluation performed at the European
Institute of Oncology. Tumor grade was assessed according to theClinical Breast Cancer February 2014criteria of Elston and Ellis10 based on the combined assessment of
tubule formation, nuclear grade, and mitotic activity.
Immunostaining for the localization of ER and PR, HER2 protein,
and Ki-67 antigen was performed on consecutive tissue sections. The
following primary antibodies were used: the 1D5 monoclonal anti-
body (MAb) to ER (1:100 dilution; Dako, Glostrup, Denmark), the
1A6 MAb to PR (1:800 dilution; Dako, Glostrup, Denmark), the
MIB-1 MAb to the Ki-67 antigen (1:100 dilution; Dako, Glostrup,
Denmark), and the A0485 polyclonal antiserum (1:400 dilution;
Dako, Glostrup, Denmark) to the HER2 protein.11 Only nuclear
reactivity was taken into account for ER, PR, and Ki-67 antigen,
whereas only an intense and complete membrane staining in > 10%
of the tumor cells qualiﬁed for HER2 overexpression (3þ). Fluores-
cence in situ hybridization assay (using the PathVysion HER2 DNA
kit, Vysis–Abbott, Des Plaines, IL) was performed in cases with
equivocal (2þ) immunohistochemical results to identify cases with
gene ampliﬁcation (HER2e chromosome 17 centromere ratio  2).
The results for ER, PR, and Ki-67 were recorded as the percentage
of immunoreactive cells observed among at least 2000 neoplastic
cells. The value Ki-67 labeling index was divided into low (< 14%)
and high ( 14%).12 The tumor was regarded as positive for ER
and PR if  1% of the cells showed nuclear staining.13
Immunohistochemical evaluation of ER, PR, Ki-67, and HER2
expression may be considered a surrogate means to identify mo-
lecular subtypes of breast cancer.12 According to the immunohis-
tochemical evaluation, we identiﬁed 4 tumor subtypes: luminal A
(ERþ or PRþ [or both], HER2 negative [HER2, Ki-67 low),
luminal B (ERþ or PRþ [or both], HER2, Ki-67 high, or ERþ or
PRþ [or both], any Ki-67, HER2 overexpressed or ampliﬁed),
HER2þ [HER2 overexpressed or ampliﬁed, ER and PR absent] and
triple negative (ER and PR absent, HER2).
Statistical Analysis
Differences in the distribution of subject characteristics between
groups were evaluated by the c2 test. The end points evaluated were
DFS, OS, cumulative incidence of local or regional recurrence (CI-
LR) and cumulative incidence of distant metastases (CI-DM). DFS
was deﬁned as the time from surgery to events such as relapse
(including ipsilateral breast recurrence), appearance of a second
primary cancer (including contralateral breast cancer), or death,
whichever occurred ﬁrst. OS was deﬁned as the time from surgery
until the date of death (from any cause). The DFS and OS functions
were estimated using the Kaplan-Meier method. The log-rank test
Figure 1 (A) Overall Survival (OS), (B) Disease-Free Survival (DFS), (C) Cumulative Incidence of Local or Regional (LR) Recurrence,
and (D) Cumulative Incidence of Distant Metastases (DM) in Patients With Breast Cancer who Present With Ipsilateral
Supraclavicular (SC) Lymph Node Metastases and Patients With Breast Cancer who Present With Internal Mammary (IM)
Lymph Node Metastases. Univariate log-Rank Test P Values and Hazard Ratios (HRs) (SC vs. IM) Adjusted for Neoadjuvant
Chemotherapy, age at Diagnosis, Number of Positive Lymph Nodes, Tumor Size, and Tumor Subtype are Reported
A
B
C D
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Adjusted HR (Supraclavicular vs. Internal Mammary), 8.72; 95% CI, 1.81-50.13 Adjusted HR (Supraclavicular vs. Internal Mammary), 4.03; 95% CI, 1.10-14.73
 P value P value
  P value    P value
Abbreviation: CI ¼ conﬁdence interval.
Silvia Dellapasqua et alwas used to assess differences between groups. The CI-LR and
CI-DM were deﬁned as the time from the date of surgery to a local
or regional recurrence and a distant metastasis, respectively.
The CI-LR and CI-DM functions were estimated according to
methods described by Kalbﬂeisch and Prentice, taking into account
the competing causes of recurrence.14 The Gray test was used to
assess cumulative incidence differences between groups.15
The hazard ratio (HR) comparing the SC group and the IM
group was estimated with a Cox proportional hazards multivariable
model controlled for neoadjuvant chemotherapy, age at diagnosis,
number of positive lymph nodes, tumor size, and tumor subtype.
The HRs comparing the IM group and its matched control group
and the SC group and its matched control group were estimated
with Cox proportional hazards univariate models.
All analyses were carried out with SAS software (SAS Institute,
Cary, NC) and the R software (http://cran.r-project.org/) with the
cmprsk package developed by Gray (http://biowww.dfci.harvard.
edu/wgray/). All reported P values are 2 sided.Results
Baseline demographic, clinical, and pathologic characteristics and
local and systemic treatments of patients with breast cancer who
presented with ipsilateral IM or SC lymph node metastases and of
2 matched comparison groups are described in Table 1. Involve-
ment of SC nodes was more frequent in patients with a high
number of positive axillary nodes, larger tumor size, triple negative
or HER2þ disease, and in those who had received neoadjuvant
treatment. As for local treatment, involvement of IM nodes was
more frequent in patients who underwent a conservative operation,
whereas involvement of SC nodes was more frequent in patients
who underwent mastectomy. The majority of patients included in
the analysis received locoregional radiotherapy.
Observed ﬁrst events and deaths in patients with ipsilateral SC or
IM lymph node metastases and of 2 matched comparison groups are
reported in Table 2. At a median follow-up of 7 years, there was a
statistically signiﬁcant difference in outcomes according to the site
of metastases (IM vs. SC) (Fig. 1): 5-year OS was 96.9% in IMClinical Breast Cancer February 2014 - 57
Figure 2 (A) Overall Survival (OS), (B) Disease-Free Survival (DFS), (C) Cumulative Incidence of Local or Regional (LR) Recurrence, and
(D) Cumulative Incidence of Distant Metastases (DM) in Patients With Breast Cancer Presenting With Internal Mammary (IM)
Lymph Node Metastases and a Matched Control Group. Univariate log-Rank Test P Values and Hazard Ratios (HRs) (IM vs.
Control) are Reported
A B
C D
 P value 
HR (Internal Mammary vs. Control), 0.93; 95% CI, .33-2.67
HR (Internal Mammary vs. Control), .86; 95% CI, .22-3.22 HR (Internal Mammary vs. Control), .69; 95% CI, .25-1.85
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HR (Internal Mammary vs. Control), 1.12; 95% CI, .59-2.11
  P value 
   P value    P value 
Abbreviation: CI ¼ conﬁdence interval.
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58 -node vs. 57.1% in SC node involvement, respectively (adjusted HR
[SC vs. IM], 7.25; 95% CI, 2.02-26.09; P < .0001) and 5-year
DFS was 84% in IM node vs. 38.8% in SC node involvement,
respectively (adjusted HR [SC vs. IM] 2.73; 95% CI, 1.15-6.45;
P < .0001). The difference was maintained both for locoregional
recurrences (cumulative incidence at 5 years, 6.2% vs. 22.6% in IM
node and SC node involvement, respectively; adjusted HR [SC vs.
IM], 8.72; 95% CI, 1.81-50.13; P ¼ .007) and for distant me-
tastases (cumulative incidence at 5 years: 6.7% vs. 32.9% in IM and
SC node involvement, respectively; adjusted HR [SC vs. IM], 4.03;
95% CI, 1.10-14.73; P ¼ .001).
The comparison of the outcome between patients with IM
lymph node involvement and the matched cohort of patients
without IM lymph node involvement did not show any statistically
signiﬁcant difference in OS (5-year OS, 96.9% vs. 93.5%; P ¼
.897), DFS (5-year DFS, 84% vs. 76.5%; P ¼ .729), locoregional
recurrences (cumulative incidence at 5 years, 6.2% vs. 5.1%; P ¼
.801), or distant metastases (cumulative incidence at 5 years, 6.7%
vs. 12.8%; P ¼ .423) (Fig. 2).Clinical Breast Cancer February 2014Conversely, the comparison between patients with SC lymph
node involvement and the matched cohort of patients without SC
lymph node involvement showed a statistically signiﬁcant difference
in DFS (5-year DFS, 38.8% vs. 58.9%; P ¼ .041) and locoregional
recurrences (cumulative incidence at 5 years, 22.6% vs. 8.6%; P ¼
.048), with a trend to different OS (5-year OS, 57.1% vs. 78%; P ¼
.068) and cumulative incidence of distant metastases (cumulative
incidence at 5 years, 32.9% vs. 24.9%; P ¼ .511), which did not
reach statistical signiﬁcance (Fig. 3).
Discussion
The results of available trials raise a number of questions about the
more appropriate treatment of patients with locally advanced breast
cancer and either IM node or SC lymph node involvement. Radical
mastectomy does not include removal of IM lymph nodes, which are
the site of occult metastases in 20% of cases. Removal of IM lymph
nodes has not been shown to improve prognosis. Postoperative
radiotherapy to the IM chain is still controversial, as it is the prog-
nostic signiﬁcance of the involvement of IM lymph nodes.
Figure 3 (A) Overall Survival (OS), (B) Disease-Free Survival (DFS), (C) Cumulative Incidence of Local or Regional (LR) Recurrence,
and (D) Cumulative Incidence of Distant Metastases (DM) in Patients With Breast Cancer Presenting With Ipsilateral
Supraclavicular (SC) Lymph Node Metastases and a Matched Control Group. Univariate log-Rank Test P Values and Hazard
Ratios (HRs) (SC vs. Control) are Reported
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HR (Supraclavicular vs. Control), 1.94; 95% CI, .94-4.01 HR (Supraclavicular vs. Control), 1.80; 95% CI, 1.02-3.20
HR (Supraclavicular vs. Control), 3.56; 95% CI, 1.11-11.41
Abbreviation: CI ¼ conﬁdence interval.
Silvia Dellapasqua et alWe found a statistically signiﬁcant difference in outcomes of
patients with SC node and IM lymph node involvement, with the
former having poorer DFS, OS, and cumulative incidence of both
locoregional recurrences and distant metastases than the latter.
In a subsequent analysis based on matched cohorts, patients with
IM lymph node involvement did not show any signiﬁcant difference
in DFS, OS, locoregional recurrences, or distant metastases
compared with their matched cohort of patients without IM node
involvement. Conversely, a signiﬁcantly worse DFS and increased
risk of locoregional recurrences were found in patients with SC
lymph node involvement compared with their matched cohort of
patients without SC lymph node involvement, with a trend to worse
OS and a cumulative incidence of distant metastases in the former
group.
In the randomized trial of mastectomy with or without IM node
dissection conducted between 1963 and 1966, 5-year survival was
the same in both groups—equal to 70%.4 In the analysis carried out
by Veronesi et al in 1985, 5-year survival was approximately 76.0%
in patients with negative axillary lymph nodes and positive IMnodes and 50.0% in patients with both nodal sites involved.7 In our
analysis, 5-year survival was 96.9% in patients with IM lymph node
involvement. As for SC lymph node involvement, 5-year survival
was 41% in the series treated at the MD Anderson Cancer Center,9
whereas we found a 5-year survival of 57.1% in patients with SC
lymph node involvement. The improvement of OS over years of
treating patients with locally advanced breast cancer and involve-
ment of IM and SC lymph nodes might well be the result of the
more tailored systemic treatments that have been available in recent
years (including adjuvant endocrine treatments with tamoxifen;
luteinizing hormoneereleasing hormone analogues or aromatase
inhibitors; adjuvant chemotherapy with anthracyclines and taxanes;
anti-HER2 adjuvant treatment with trastuzumab), and possibly
radiotherapy to the IM chain and to the SC fossa.
SC lymph nodes as well as IM nodes are part of a continuum in
the regional lymphatic drainage of the breast. Axillary lymph nodes
levels 1 to 3, SC lymph nodes, and IM nodes are not separated on
the basis of functional differences but according to arbitrary
anatomical boundaries.Clinical Breast Cancer February 2014 - 59
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60 -In our study, SC lymph node involvement correlated with a
signiﬁcantly poorer outcome in patients with locally advanced breast
cancer. Adequate staging, including biopsy of suspicious locore-
gional (IM or SC) ipsilateral lymph nodes, is mandatory in these
patients because it may affect treatment.7 Lymph node biopsy of
both SC and IM nodes is a simple and safe procedure that provides
useful information to apply to targeted radiotherapy in selected
cases.
Moreover, based on our results, we endorse the recommendation
to treat patients with either IM or SC lymph node involvement
with curative intent using combined-modality therapy (surgery,
radiotherapy, chemotherapy, hormonal therapy in women with
ERþ tumors, and anti-HER2 therapy in women with HER2
overexpressed/ampliﬁed tumors).9 Such treatments provide these
patients with the maximum chance of long-term DFS and OS.
Clinical Practice Points
 Prognostic implications of internal mammary (IM) and supra-
clavicular (SC) node involvement in locally advanced breast
cancer is still unclear, and therapeutic choices in cases where IM
and /or SC lymph nodes are involved are still not uniformly
deﬁned.
 We evaluated 107 patients with IM or SC node involvement,
and a matched cohort of patients as controls. Five-year disease-
free survival (DFS) was 84% in IM vs. 38.8% in SC node
involvement (P < .0001), and 5-year overall survival (OS) was
96.9% in IM node vs. 57.1% in SC node involvement (P <
.0001). No outcome differences were found between patients
with and controls without IM node involvement, whereas a
statistically signiﬁcant difference in DFS and locoregional
recurrence was observed in patients with compared with controls
without SC node involvement.
 Adequate staging, including biopsy of suspicious loco-regional
ipsilateral lymph nodes, is mandatory in these patients. PatientsClinical Breast Cancer February 2014with IM or SC node involvement should be treated with curative
intent using combined-modality treatments.
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